论文部分内容阅读
系统性红斑狼疮(SLE)是以多种自身抗体导致不同靶器官损害为特点的自身免疫性疾病,B细胞靶向治疗危重性、难治性病例是目前临床研究的热点和难点,包括抗CD20/CD22阳性B细胞靶向治疗和BAFF拮抗药,其中以利妥昔单抗和贝利单抗临床最常用,且安全有效,其他多数制剂仍在不同阶段的临床试验中。未来研究应在多中心研究的基础上,更专注于理想SLE患者的选择、初始治疗时机的选择、治疗药物的选择以及终止或撤减治疗方法的选择。
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by various autoantibodies leading to different target organ damage. B cell targeting therapy is a hot and difficult issue in clinical research at present, including anti-CD20 / CD22 positive B cell targeting therapy and BAFF antagonists, of which rituximab and belimumab are clinically most commonly used and safe and effective, and most other preparations are still in different stages of clinical trials. Future research should focus more on the selection of patients with ideal SLE, on the timing of initial treatment, on the choice of treatment medication, and on the choice of stopping or withdrawing treatment based on multicenter studies.